Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus CEPHAPIRIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus CEPHAPIRIN SODIUM.
CEFADYL vs CEPHAPIRIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
500 mg to 1 g IM or IV every 6 hours.
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic